Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)
China · Delayed Price · Currency is CNY 53.00
-0.82 (-1.52%)
At close: Feb 6, 2026
SHA:688192 Revenue
Dizal (Jiangsu) Pharmaceutical had revenue of 231.30M CNY in the quarter ending September 30, 2025, with 71.46% growth. This brings the company's revenue in the last twelve months to 607.75M, up 55.98% year-over-year. In the year 2024, Dizal (Jiangsu) Pharmaceutical had annual revenue of 359.90M with 294.24% growth.
Revenue (ttm)
607.75M
Revenue Growth
+55.98%
P/S Ratio
40.52
Revenue / Employee
713.32K
Employees
985
Market Cap
24.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 359.90M | 268.61M | 294.24% |
| Dec 31, 2023 | 91.29M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 10.29M | -17.48M | -62.95% |
| Dec 31, 2020 | 27.76M | -13.26M | -32.32% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Joincare Pharmaceutical Group Industry | 15.20B |
| Livzon Pharmaceutical Group | 11.85B |
| Apeloa Pharmaceutical Co.,Ltd | 10.50B |
| Zhejiang Huahai Pharmaceutical | 8.71B |
| Tasly Pharmaceutical Group | 8.35B |
| Hubei Jumpcan Pharmaceutical | 6.14B |
| Jiangsu Nhwa Pharmaceutical Co., LTD | 6.02B |
| Kangmei Pharmaceutical | 5.28B |